EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1RA IN PEOPLE WITH OVERWEIGHT OR OBESITY: A PHASE 3, MULTI-CENTER RANDOMIZED, CONTROLLED TRIAL (VESPER-4)

Condition studied

Obesity

Investigational medicinal product(s)

Every trial of Berobenatide across our registers →

Eligibility

Primary endpoint

Percent change from baseline in body weight at Week 64

Endpoint detail

Change from baseline in body weight (kg) at Week 64, Occurrence at Week 64 of: • CCI % of reduction from baseline body weight • CCI% of reduction from baseline body weight • CCI % of reduction from baseline body weight • O CCI % of reduction from baseline body weight, Change from baseline at Week 64 in: • Fasting triglycerides (mg/dL) • O Non-high-density lipoprotein-cholesterol (non-HDL-C) (mg/dL), Change from baseline in SBP (mmHg) at Week 64, Change from baseline in Short Form 36 health survey (SF-36) physical function domain score at Week 64, Percent change from baseline in body weight at Week 84, Change from baseline in body weight (kg) at Week 84